T. Rowe Price Associates
NAUT icon

T. Rowe Price Associates’s Nautilus Biotechnolgy NAUT Stock Holding History

T. Rowe Price Associates’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,078
Closed -$14K – 3118
2025
Q1 		$14K Hold
16,078
– – ﹤0.01% 3019
2024
Q4 		$28K Hold
16,078
– – ﹤0.01% 2981
2024
Q3 		$46K Hold
16,078
– – ﹤0.01% 2938
2024
Q2 		$38K Hold
16,078
– – ﹤0.01% 2883
2024
Q1 		$48K Buy
16,078
+4,239
+36% +$12K ﹤0.01% 2877
2023
Q4 		$36K Buy
11,839
+1,389
+13% +$3.97K ﹤0.01% 2844
2023
Q3 		$34K Buy
10,450
+438
+4% +$1.43K ﹤0.01% 2822
2023
Q2 		$39K Buy
+10,012
New +$28.8K ﹤0.01% 2827

Other funds holding NAUT

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $2.32B AUM 30.12% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.01B AUM 2.93% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

T. Rowe Price Associates's NAUT Position: Q2 2025 in Review

T. Rowe Price Associates sold out of Nautilus Biotechnolgy (NAUT) in Q2 2025, closing a stake of 16,078 shares — an estimated $14K sold.

T. Rowe Price Associates first reported a position in NAUT in Q2 2023 and held it in 8 quarters. The position peaked at $48K in Q1 2024. 71 funds tracked by Wall St. Rank hold NAUT as of Q2 2025.

  • T. Rowe Price Associates reported no remaining Nautilus Biotechnolgy position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 16,078 Nautilus Biotechnolgy shares in Q2 2025, an estimated $14K.
  • T. Rowe Price Associates first reported a position in Nautilus Biotechnolgy in Q2 2023 and held it in 8 quarters.
  • T. Rowe Price Associates's Nautilus Biotechnolgy position peaked at $48K in Q1 2024.
  • 71 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.